SEC Form 4 · accession 0001179110-15-001132
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Knopf
Officer — CEO and President · Director
Period of report
Jan 21, 2015
Accepted (ET)
Jan 22, 2015 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 21, 2015 | M | 12,500 | $0.40 | A | 69,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $0.40 | Jan 21, 2015 | M | 12,500 | D | — | Feb 2, 2015 | Common Stock | 12,500 | 0 | D |
Explanation of responses
- F1The options of registrants common stock vested 25% on the first anniversary of the grant and in equal installments quarterly thereafter.